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Abstract
Introduction Retroperitoneal ﬁbrosis is a ﬁbroinﬂamma-
tory disease of unknown etiology that can be associated
with other ﬁbroinﬂammatory disorders. Lately, there have
been several reports showing that retroperitoneal ﬁbrosis is
a manifestation of IgG4-related sclerosing disease, which
often presents as autoimmune pancreatitis.
Case report This report shows the case of IgG4-related
sclerosing cholangitis associated with retroperitoneal
ﬁbrosis independent of autoimmune pancreatitis. The
patient presented with cholestatic jaundice and picture of
sclerosing cholangitis in endoscopic retrograde cholangi-
ography. The combination of endoscopic biliary drainage
and steroid therapy was an effective treatment in this case.
Conclusion The diagnosis of IgG4-related sclerosing
disease should always be taken into consideration in
patients with sclerosing cholangitis, especially when it is
associated with any ﬁbroinﬂammatory disorder.
Keywords Sclerosing cholangitis  Retroperitoneal
ﬁbrosis  Multisystem ﬁbroinﬂammatory disorder 
IgG4-related sclerosing disease
Introduction
Retroperitoneal ﬁbrosis (also known as Ormond’s disease)
is a rare disorder characterized by the presence of ﬁbro-
inﬂammatory tissue in the retroperitoneal space, which
usually surrounds the abdominal aorta and iliac arteries [1].
The pathogenesis of the disease remains unclear. It seems
that autoimmune mechanisms play a crucial part in the
induction of chronic inﬂammation and ﬁbrosis. It is difﬁ-
cult to state whether it is a localized process or just a
manifestation of a systemic disease. The frequent associ-
ation of retroperitoneal ﬁbrosis with autoimmune diseases
(e.g., systemic lupus erythematosus, rheumatoid arthritis,
vasculitis, autoimmune thyroid diseases) and ﬁbrosis of
additional organs (e.g., sclerosing cholangitis, orbital
pseudotumor, Riedel’s thyroiditis) suggest the systemic
mechanism of the disease. Therefore, retroperitoneal
ﬁbrosis is regarded by some authors as one of the mani-
festations of a multisystem ﬁbroinﬂammatory disorder [2].
Lately, a new term ‘‘IgG4-related sclerosing disease’’ has
beenproposedtodescribethegroupofautoimmunedisorders
involving connective tissue. Kamisawa et al. have demon-
strated IgG4 antibody-stained plasma cells in a number of
organs and proposed a new clinicopathological entity of
IgG4-related autoimmune diseases. The authors suggested
that stricture of the bile duct, sialadenitis or autoimmune
pancreatitis were induced by extensive IgG4-positive plasma
cellinﬁltrationoforgans,togetherwithCD4-orCD8-positive
T-lymphocytes. Clinical manifestation is apparent in the
organs in which tissue ﬁbrosis is pathologically induced
and it is characterized by clinical improvement on steroid
therapy[3].TheinﬁltrationofIgG4-positiveplasmacellsand
T-lymphocytes has been observed in various organs: pan-
creas, bile ducts, gallbladder, salivary glands, retroperito-
neum, kidneys, lungs and prostate. Most manifestations of
IgG4-related sclerosing disease are associated with autoim-
mune pancreatitis, but there are also cases without pancreas
involvement as in the case of our patient [4–7].
There are few case reports of Ormond’s disease with
involvement of the bile ducts. In most of them, the
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presented retroperitoneal ﬁbrosis with involvement of the
intrahepatic bile ducts and the image of sclerosing cho-
langitis [16–18]. Diagnosing IgG4-related sclerosing cho-
langitis remains a great clinical challenge, especially if is
not associated with autoimmune pancreatitis. It needs to be
differentiated from primary sclerosing cholangitis (PSC)
and cholangiocarcinoma, as it results in completely dif-
ferent therapeutic strategy. Such diagnosis should always
be taken into account in patients with cholangiographic
picture of sclerosing cholangitis, especially if it coexists
with any other potential IgG4-related disease. Diagnostic
difﬁculties lead to unnecessary surgery in many patients
and some of them may be left without an appropriate
therapy. This report shows the case of IgG4-related scle-
rosing cholangitis associated with retroperitoneal ﬁbrosis
independent of autoimmune pancreatitis.
Case report
A 51-year-old man was admitted to the Department of
Gastroenterology and Hepatologyof the Medical University
inGdanskinJanuary2007becauseofincreasing jaundiceof
a few weeks, severe pruritus, fatigue, loss of appetite and
weight loss up to 30 kg in the 4 preceding months.
His medical history was signiﬁcant for Ormond’s dis-
ease diagnosed 2 years earlier. The disease presentation at
that time was acute renal failure due to obstructive urop-
athy. Other etiologic factors of retroperitoneal ﬁbrosis were
excluded and steroid therapy was applied with good clin-
ical effect. Total IgG level was elevated at that time,
27.44 g/L (5.4–20.34 g/L), but no assessment of IgG4 level
was performed. The patient had also suffered from hypo-
thyroidism due to Hashimoto’s thyroiditis for 26 years and
arterial hypertension for 10 years. He was using the fol-
lowing medications: methylprednisolone 4 mg daily, per-
indopril and levothyroxine 100 lg daily.
Physical examination revealed jaundice, skin excoria-
tions and hepatomegaly. There was no tenderness of the
abdomen.
In the initial laboratory tests, the following pathologies
were observed (reference values in parentheses): anemia—
hemoglobin level 111 g/L (140–180 g/L), erythrocyte sed-
imentation rate 58 mm/h (2–20 mm/h), total bilirubin
589.95 lmol/L (3.4–20.5 lmol/L), alkaline phosphatase
228 U/L (40–150 U/L) and the presence of anti-HCV
antibodies (later conﬁrmed with HCV RNA test). Hepatitis
B was excluded. Electrolytes, coagulation tests, C-reactive
protein, and glucose and liver function tests other than
alkaline phosphatase were within normal limits. The patient
was also tested for autoimmune liver diseases: antineutro-
phil cytoplasmic antibodies (ANCA), smooth muscle cells
antibodies (SMA) and antimitochondrial antibodies (AMA)
were within normal limits; antinuclear antibodies (ANA)
were elevated to 320 (\1:40) and bile duct antibodies
(BDA) to 20 (\1:5), which were not speciﬁc. Total IgG
level was normal on admission, but an elevated concentra-
tion of IgG4 (at 2.46 g/L [0.03–2.0 g/L]) was noted during
hospitalization. Apart from that, an increase in thyroid-
stimulating hormone (TSH) serum level to 36.38 lU/mL
(0.34–4.94 lU/mL) and a decrease in free thyroxine (T4)
serum level to 10.18 pmol/L (9.01–19.05 pmol/L) was
observed on admission to the hospital. The dose of levo-
thyroxine was increased to 150 lg/daily with good clinical
effect (after a few months, TSH level was 5.6 lU/mL and
T4 was 14.7 pmol/L).
Abdominal ultrasonography showed hepatomegaly,
dilated intrahepatic bile ducts and no signs of cholelithia-
sis, tumor of pancreas or liver hilus. Abdominal CT
revealed hepatomegaly with marked cholestasis in both
hepatic lobes, thickening of the gallbladder wall and a 5-
mm mantle of soft tissue along the ventral side of the aorta
that reﬂected sclerosing changes in the course of Ormond’s
disease (Fig. 1a, b).
Endoscopic retrograde cholangiopancreatography
(ERCP) was performed, which revealed segmental stric-
tures of the right hepatic duct with post-stenotic dilation
(Fig. 2). There were no stones in the bile duct. The main
stricture of the right hepatic duct was mechanically dilated
and nasobiliary drain and biliary stent were placed into the
right hepatic lobe. The pancreatic duct was normal.
In the course of therapy, repeated lavage of bile ducts with
saline solution was performed and corticosteroids were
administered (ﬁrst methylprednisolone intravenously and
then prednisone orally). The patient also received ursode-
oxycholic acid. In a bile culture, Streptococcus viridans was
present and amoxicillin ? clavulanic acid was administered.
After 9 days of hospital stay, fever over 38.5C
appeared and cholangitis was diagnosed. Bile culture
revealed Acinetobacter baumanii infection and the antibi-
otic was changed to imipenem (according to microbial
sensitivity test). Another ERCP was performed, which
showed multifocal strictures of intrahepatic bile ducts.
Nasobiliary drain in the right hepatic duct was replaced
with a stent, and a drain and a stent were placed into the
left hepatic duct. The bile ducts’ lavage, antibiotics and
corticosteroids were continued with good clinical effect.
After 7 weeks of biliary lavage and steroid therapy, total
bilirubin level was 32.49 lmol/L (3.4–20.5 lmol/L),
gamma-glutamyltransferase was 190 U/L (8–61 U/L), and
other liver enzymes and laboratory tests were within nor-
mal limits. During ERCP, nasobiliary drain was replaced
with a biliary stent. Follow-up CT revealed only moderate
intrahepatic cholestasis (Fig. 3). Methylprednisolone dose
was gradually tapered. The biliary stent was replaced after
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1236 months, at which time the patient’s general condition was
good and laboratory tests were unremarkable.
Another abdominal CT performed in April 2008 revealed
a signiﬁcant decrease of intrahepatic cholestasis in com-
parison to the CT from January 2007. There was only a
moderate dilation of bile ducts in the left hepatic lobe and in
the hilar region. In July 2008, ERCP was performed, biliary
stents were removed and no strictures of bile ducts were
visible. The patient was feeling well; physical examination
and laboratory tests were unremarkable. Another abdominal
CT in September 2009 revealed complete regression of both
cholestasis and pathological mass around the abdominal
aorta (Fig. 4a, b). At the 3-year follow-up, the patient is
doing well with no signs of disease relapse and continues to
take methylprednisolone 8 mg daily.
Discussion
Most reports presenting retroperitoneal ﬁbrosis associated
with the involvement of bile ducts were related to cases of
obstruction of the common bile duct at the level of the
pancreatic head due to autoimmune pancreatitis [8–15]. In
those case reports, clinical picture and imaging studies
Fig. 1 CT showing
hepatomegaly with cholestasis
in both hepatic lobes (a) and
mantle of soft tissue along the
ventral side of aorta–arrow (b)
Fig. 2 ERCP showing segmental strictures (thin arrow) of the right
hepatic duct with post-stenotic dilation (thick arrow)
Fig. 3 CT showing moderate intrahepatic cholestasis in both lobes;
stents in hepatic bile ducts (arrow)
Hepatol Int (2010) 4:779–783 781
123suggested the diagnosis of pancreatic cancer or cholangi-
ocarcinoma, and the patients underwent surgical treatment
with histological assessment. In the case of our patient,
endoscopic retrograde cholangiography revealed multiple
strictures of intra- and extrahepatic bile ducts, as in scle-
rosing cholangitis. Similar cases of sclerosing cholangitis
associated with retroperitoneal ﬁbrosis were previously
reported by Bartholomew in the 1960s and Laitt in the
1990s [19, 20]. Recently, there have been a few reports of
Ormond’s disease associated with sclerosing cholangitis. In
those patients, elevation of IgG and IgG4 level was
observed, as well as coexistence of other autoimmune
diseases such as sclerosing pancreatitis, sialadenitis and
Sjo ¨gren’s syndrome [16–18]. In 2007, a new term ‘‘IgG4-
associated cholangitis’’ (IAC) has been introduced refer-
ring to the biliary manifestation of IgG4-related systemic
disease [6, 21]. In 2008, Ghazale presented the HISORt
criteria for diagnosis of IAC [21]. In cases in which fea-
tures of sclerosing cholangitis are visible on cholangiog-
raphy, the diagnosis of both PSC and IAC should be
considered. Both PSC and IAC are characterized by intra-
and extrahepatic strictures of the bile ducts; therefore,
cholangiography is similar in both disorders and is not a
differentiating diagnostic tool [22, 23]. Patients with IAC
respond to steroid therapy, while patients suffering from
PSC are resistant to steroids and eventually need liver
transplant. In contrast to PSC, IAC is not associated with
inﬂammatory bowel diseases, but it usually coexists with
ﬁbroinﬂammatory changes in other organs such as pan-
creas, salivary glands, retroperitoneal space, lymph nodes
and kidneys. IAC is most often associated with autoim-
mune pancreatitis, but pancreatic disease is not essential
for the diagnosis of IAC [4, 21, 22]. IAC is characterized
by elevation of serum IgG4 level and lymphoplasm-
acytic inﬁltration (with [10 IgG4-positive cells/hpf) on
histological examination inside or around the bile ducts
[7, 23, 24].
In the case of our patient, ERCP revealed multiple seg-
mental strictures of intrahepatic bile ducts that could occur
both in PSC and IAC. Good response to steroid treatment,
association with other ﬁbroinﬂammatory diseases such as
retroperitoneal ﬁbrosis and Hashimoto thyroiditis, elevation
of serum IgG at the moment of diagnosis of retroperitoneal
ﬁbrosis and IgG4 in the course of therapy of sclerosing
cholangitis suggest the diagnosis of IAC. There was no need
for surgery and no biopsy of bile ducts was performed.
However, even without histological examination, taking
into account all the data mentioned above, we can classify
our patient into the group of high index of suspicion of IAC
and we can exclude PSC. Sclerosing pancreatitis associated
with retroperitoneal ﬁbrosis is described by many authors as
‘‘autoimmune pancreatitis’’ due to multisystem ﬁbroin-
ﬂammatory disorder or IgG4-related sclerosing disease [5,
14]. Therefore, it seems that the cases of sclerosing cho-
langitis due to retroperitoneal ﬁbrosis, as in the patient
described above, are most probably the biliary manifesta-
tion of steroid-responsive multisystem ﬁbroinﬂammatory
disorder [5]. It is important to single out those patients and
differentiate IAC from PSC, because of completely differ-
ent therapeutic strategies. In the case of our patient, the
combination of steroid therapy and endoscopic drainage of
the bile ducts was performed to reduce the very high bili-
rubin level as fast as possible, and to prevent the potential
fatal consequences of very high hyperbilirubinemia and
cholangitis. Ghazale et al. had also performed biliary
stenting to fasten the resolution of jaundice [21]. The
question remains how long the treatment should be con-
tinued. There are no data on what the duration of IAC
therapy should be. Maybe, the repeated assessment of
serum IgG4 level could be a useful marker for monitoring
and planning the continuation of treatment.
In the case of our patient, we can also discuss whether
there was an association between sclerosing cholangitis
and Hashimoto thyroiditis, or if they occurred
Fig. 4 CT showing complete
regression of both cholestasis
(a) and pathological mass
around the abdominal aorta (b)
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123coincidentally. Recently, Li et al. have found similar his-
topathological features to IgG4-related sclerosing disease
in the ﬁbrous variant of Hashimoto autoimmune thyroiditis.
The authors proposed a new classiﬁcation by which Ha-
shimoto autoimmune thyroiditis can be subclassiﬁed into
two groups: IgG4 thyroiditis and non-IgG4 thyroiditis.
IgG4 thyroiditis may be closely related to IgG4-related
sclerosing disease [25, 26]. There was no need for biopsy
of the thyroid gland in our patient; therefore, we cannot
prove that it was an IgG4 thyroiditis. However, the exac-
erbation of hypothyroidism at the time of diagnosis of IAC
and the need for an increase of levothyroxine dose after
many years of stable thyroid disease might suggest some
association between those two autoimmune disorders.
The diagnosis of IgG4-related sclerosing disease should
always be taken into consideration in patients with scle-
rosing cholangitis, especially when it is associated with any
ﬁbroinﬂammatory disorder. In the case of the patient pre-
sented above, the combination of repeated and complicated
endoscopic biliary drainage with steroids turned out to be
an effective and complementary therapeutic strategy.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
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